Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Recurrent IgA Nephropathy
NCT02571842Phase 4Unknown
- Sponsor
- Chulalongkorn University
- Start
- Jan 2012
- Primary completion
- Dec 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab in IgA nephropathy (IgAN) (2 arms), sponsored by Chulalongkorn University. Primary endpoints: Remission rate at 12 months and Incidence of all adverse events at 12 months. Status: unknown.
02
Drugs
rituximab
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT02571842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571842.